Ovid Therapeutics Inc. (OVID)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Ovid Therapeutics Inc. reported revenue of $7.25M, up 1181.3% from the prior year. The company ran a net loss, with a net margin of -240.1%. It held $150.93M in total assets against $20.27M in total liabilities.
Key ratios (FY2025)
-585.2%
Operating margin
-240.1%
Net margin
-13.3%
Return on equity
+1181.3%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.25M | $566.0K | $392.0K | $1.50M | $208.38M | — | — | — | — | — |
| Operating Income | -$42.44M | -$61.88M | -$59.28M | -$55.55M | $124.21M | -$81.43M | -$61.41M | -$52.93M | -$65.01M | -$22.54M |
| Net Income | -$17.41M | -$26.43M | -$52.34M | -$54.17M | $122.83M | -$81.04M | -$60.46M | -$51.98M | -$64.81M | -$22.41M |
| EPS (Diluted) | — | — | $-0.74 | $-0.77 | $1.76 | $-1.39 | — | — | — | — |
| Total Assets | $150.93M | $92.17M | $144.03M | $155.27M | $194.54M | $75.93M | $80.84M | $47.65M | $89.46M | $53.03M |
| Total Liabilities | $20.27M | $23.94M | $56.23M | $22.99M | $14.80M | $32.29M | $10.82M | $8.84M | — | — |
| Shareholders' Equity | $130.66M | $68.23M | $87.80M | $132.27M | $179.75M | $43.63M | $70.02M | $38.81M | $83.44M | $49.29M |
| Cash & Equivalents | $13.15M | $26.30M | $27.04M | $44.87M | $187.80M | $72.03M | $41.90M | $36.49M | $87.13M | $51.94M |
| Operating Cash Flow | -$38.33M | -$55.96M | -$45.78M | -$55.23M | $118.61M | -$51.58M | -$51.09M | -$45.56M | -$31.47M | — |
| Capital Expenditures | $0 | $71.0K | $40.0K | $1.22M | $184.0K | $127.2K | $57.2K | $33.9K | $38.9K | $30.4K |
| Shares Outstanding | 130.18M | 71.01M | 70.69M | 70.47M | 70.36M | 65.74M | 54.71M | 24.65M | 24.61M | 9.84M |